企业如何选择适合自己的重磅炸弹.ppt

Power of Two
企业如何选择适合自己的“重磅炸弹”
Bill Guo
国际知名企业如何开展新药/通用名药的研究
葛兰素史克
Dr Reddy’s Lab
Venturepharm
Fast Facts:
FY 2002 (April 1 – March 31) Sales: $340 million
Net Profit: $101 million
EPS: $
Cash Reserve: $120 million
Market Capitalization: $ billion (9/18/02)
Shares Outstanding: million
A Record of Achievement:
First Asia/Pacific* company listed on NYSE, April 2001: RDY
First India-pany to:
Receive 180-day exclusivity for generic drug in the .
File an NDA under Sec. 505(b)(2) (amlodipine maleate)
License an NCE to a multinational firm
*Excluding Japan
An Emerging Pharmaceutical Firm
Key Research Facilities
Aurigene Discovery Technologies
(Boston)
Bangalore Labs/ Aurigene*
(Bangalore)
. Therapeutics
(Atlanta)
Dr. Reddy’s Research Foundation
Technology Development Center
*December 2002
Drug Discovery Scientists: 260
Process Research Center
Discovery Research
Process Research
Discovery Services Center
Strategic Overview
*Less Regulated Market
New
Chemical
Entities
Longer-Term
Specialty
Rx
Mid-Term
Generics
Near-Term
Branded Generics*
Active Pharmaceutical
Ingredients
Base
Business
Time
Driving Value
Pain
Management
DRF 4848
Phase I
Phase II
Phase III
Pre-clinical
Trials
Clinical Trials
Metabolic
Disorders
DRF 4832
DRF 4158
*
* Licensed to Novartis
Cancer
DRF 3188
DRF 1644
DRF 1042
Diabetes
DRF NPPC
DRF 2593
DRF 27251
** Licensed to Novo Nordisk
**
**
1Development status to be determined Q1/2003
NCE Pipeline: Driving Growth Longer-Term